Tumor Vaccine Development, Immune-Based Therapies and Immune Markers
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1972
Special Issue Editors
Interests: head and neck cancer; immunotherapy; translational research
Special Issues, Collections and Topics in MDPI journals
Interests: breast cancer; immunotherapy; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, there has been substantial progress in the development of new therapeutic strategies against tumors. The significance of immunotherapy in this field is increasing, and the importance of understanding the interaction between tumor cells and the immune system is dramatically growing.
A deeper understanding of the multiple immunosuppressive mechanisms leading to tumor escape is paving the way for the development of an incredible number of new immunotherapies.
Similarly, the enormous ongoing effort to identify reliable markers of response will enable personalized therapies.
Finally, after many disappointing experiences in the past, greater knowledge of the tumor microenvironment and of the immune response mechanisms have improved the expectations which can be placed on anti-tumor vaccines.
Indeed, tumor vaccination has swiftly expanded over the last few years to incorporate in vitro approaches such as T-cell transfer therapy, in situ vaccination, and the use of oncolytic viruses, all with the purpose of inducing antitumor response.
In combination with the other strategies, including chemotherapy, monoclonal antibodies, radiation therapy, and different immunotherapeutic approaches involving immune checkpoint inhibitor therapy, cancer vaccines will become soon an important new tool in fighting cancer.
This Special issue is focused on the recent scientific research, progress, and achievements in the fields of immunotherapy against cancer, the effectiveness of cancer vaccines on tumors and tumor microenvironment. We invite and welcome all scholars to contribute with original articles, systematic reviews, short communications, and other types of articles on related topics are welcome.
Dr. Marco Carlo Merlano
Dr. Ornella Garrone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- new immunotherapy strategies
- anticancer vaccines
- tumor microenvironment-associated markers of response
- mechanisms of primary and secondary immune resistance
